.Pharmacolibrary.Drugs.ATC.N.N06AX16

Information

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It is an approved medication and is widely used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult volunteers after single oral dose administration.

References

1. Fukuda, T, et al., & Azuma, J (2000). The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. European journal of clinical pharmacology 56(2) 175–180. DOI:10.1007/s002280050737 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10877013

2. Lindh, JD, et al., & AL-Shurbaji, A (2003). Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. European journal of clinical pharmacology 59(5-6) 401–406. DOI:10.1007/s00228-003-0627-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12898080

3. McGrane, IR, et al., & Munjal, RC (2021). Roux-en-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases. Journal of pharmacy practice 34(3) 503–506. DOI:10.1177/0897190020905467 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32067562

Revisions

• 06/2025 initial generated model